Use of Antiplatelet Therapy after Percutaneous Coronary Intervention with Bare-Metal Stents and Different Types of Drug-Eluting Stents

Publisher： Bentham Science Publishers

E-ISSN： 2212-3938|8|1|59-66

ISSN： 1574-8847

Source： Current Clinical Pharmacology, Vol.8, Iss.1, 2013-02, pp. : 59-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adverse event profile similar for drug-eluting and bare-metal stents

By  

Reactions Weekly, Vol. 1, Iss. 1170, 2007-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Adverse event profile similar for drug-eluting and bare-metal stents

By  

Inpharma, Vol. 1, Iss. 1606, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Optimal Duration of Antiplatelet Therapy in Recipients of Coronary Drug-Eluting Stents

By Zimarino Marco   Renda Giulia   Raffaele De Caterina  

Drugs, Vol. 65, Iss. 6, 2005-01 ,pp. : 725-732

Adis International

Access to resources Recommend Favorite

Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents

By  

Current Drug Targets, Vol. 10, Iss. 6, 2009-06 ,pp. : 519-529

Bentham Science Publishers

Access to resources Recommend Favorite

Drug-Eluting Stents in Percutaneous Coronary Intervention: A Benefit-Risk Assessment

By Byrne Robert A.   Sarafoff Nikolaus   Kastrati Adnan   Schömig Albert  

Drug Safety, Vol. 32, Iss. 9, 2009-09 ,pp. : 749-770

Adis International

Access to resources Recommend Favorite